Related Experiment Video
Updated: Jun 27, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Clostridium chauvoei Antigens: Applications, Available Options and Potential Alternatives in the Future
1Department of Anaerobic Bacterial Vaccines Research and Production, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. a.zahmatkesh@rvsri.ac.ir.
None:
Clostridium chauvoei is a gram-positive spore-forming anaerobic bacterium and the cause of blackleg, a highly fatal endogenous disease in ruminants. The bacterium produces both cellular (somatic and flagellar) and soluble antigens (toxins) that contribute to the pathogenesis. Immunity to C. chauvoei is primarily anti-bacterial, and so the traditional vaccines are formalinized whole-culture bacterins. The current research focuses on identifying specific antigens as immuno-protective antigens including cell surface or flagellar proteins or soluble antigens. This paper summarizes the application of C. chauvoei immunogens for detection or vaccine quality control, and reviews the ongoing research into developing more targeted subunit vaccines using recombinant or purified antigens like CctA or flagellin. Despite high genomic similarity in virulence factors among C. chauvoei strains, differences in the fliC gene encoding flagellin exist. Hence, strain differences may affect the protection efficacy against Blackleg disease. The development of effective Blackleg subunit vaccines necessitates careful consideration of the C. chauvoei strain, antigen purification techniques, bacterial growth phase and the preservation of crucial conformational epitopes in recombinant technology.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Clinical Significance of Antibiotic Resistance